DOCSLIB.ORG

Thyroid Hormone Transporters

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thyroid Hormone Transporters Review Thyroid Hormone Transporters Stefan Groeneweg,1 Ferdy S. van Geest,1 Robin P. Peeters,1 Heike Heuer,2 and Downloaded from https://academic.oup.com/edrv/article-abstract/41/2/bnz008/5637505 by Erasmus University Rotterdam user on 04 March 2020 W. Edward Visser1 1Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands Academic Center for Thyroid Diseases, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands; and2 Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Essen 45122, Germany ORCiD numbers: 0000-0002-5248-863X (W. E. Visser). ABSTRACT Thyroid hormone transporters at the plasma membrane govern intracellular bioavailability of thyroid hormone. Monocarboxylate transporter (MCT) 8 and MCT10, organic anion transporting polypeptide (OATP) 1C1, and SLC17A4 are currently known as transporters displaying the highest specificity toward thyroid hormones. Structure-function studies using homology modeling and muta- tional screens have led to better understanding of the molecular basis of thyroid hormone transport. Mutations in MCT8 and in OATP1C1 have been associated with clinical disorders. Different animal models have provided insight into the functional role of thyroid hormone transporters, in particular MCT8. Different treatment strategies for MCT8 deficiency have been explored, of which thyroid hormone ana- logue therapy is currently applied in patients. Future studies may reveal the identity of as-yet-undiscovered thyroid hormone transporters. Complementary studies employing animal and human models will provide further insight into the role of transporters in health and disease. (Endocrine Reviews 41: 1 – 55, 2020) GRAPHICAL ABSTRACT Thyroid Blood Brain barriers Brain = TSH Astrocyte Oligodendrocyte HEALTH = T4 Neuron = T3 Bone Heart Muscle ISSN Print: 0163-769X ISSN Online: 1945-7189 Thyroid Blood Brain barriers Brain Printed: in USA = TSH Astrocyte Oligodendrocyte © Endocrine Society 2019. Neuron All rights reserved. For T4 DISEASE permissions, please e-mail: [email protected] T3 ISSN Print: 0163-769XISSN Online: 1945-7189Printed: in USA Received: 31 May 2019 Bone Heart Muscle Accepted: 7 November 2019 First Published Online: 22 Key Words: thyroid hormone, thyroid hormone transport, thyroid hormone transporters, MCT8, November 2019 MCT8 deficiency, Allan-Herndon-Dudley syndrome, AHDS, OATP1C1 Corrected and Typeset 13 February 2020. doi: 10.1210/endrev/bnz008 https://academic.oup.com/edrv 1 Review ESSENTIAL POINTS • Thyroid hormones require transporter proteins to facilitate their transport across cell membranes • Among the up to 16 different thyroid hormone transporters belonging to 5 distinct protein families; monocarboxylate transporter 8 (MCT8) is the most specific thyroid hormone transporter identified to date Genetic mutations in MCT8 and organic anion transporting polypeptide (OATP) 1C1 have been associated with clinical • Downloaded from https://academic.oup.com/edrv/article-abstract/41/2/bnz008/5637505 by Erasmus University Rotterdam user on 04 March 2020 syndromes • MCT8 deficiency (Allan-Herndon-Dudley syndrome) is characterized by a neurocognitive (central) entity related to a hypothyroid state in the brain and a peripheral entity due to T3 excess in the circulation • Treatment strategies for MCT8 deficiency that are currently being explored include thyroid hormone analogue therapy, (molecular) chaperones, and gene therapy hyroid hormone, the common name for early studies, providing the basis for a paradigm T the inactive precursor thyroxine (T4) and shift in the field, have been extensively reviewed the active hormone 3,5,3’-tri-iodothyronine (T3), in this Journal by Hennemann et al (2001) (8). The is important for the development of virtually all turn of the millennium marked the time of several tissues and regulation of basal metabolism and discoveries that had a great impact on the field of tissue regeneration throughout life (1, 2). thyroidology. The genomic effects of thyroid hormone are First, several transporters from different pro- exerted through binding of T3 to the nuclear T3 tein families were identified at the molecular receptors (TRs), which are bound to T3-response level as thyroid hormone–transporting proteins. elements (TREs) in the regulatory regions of T3 This was a major breakthrough compared to the target genes and can act as transcription factors (2). decades before when only the general character- The intracellular T3 concentration is governed by istics of thyroid hormone transmembrane pas- the 3 deiodinating enzymes (DIO1-3) that can ei- sage had been studied in nontransfected cells. ther activate or inactivate thyroid hormone, as well The most efficient thyroid hormone transporters as by the activity of plasma membrane transporter include monocarboxylate transporter (MCT)8, proteins that mediate the cellular uptake and/or ef- MCT10, the organic anion transporting polypep- flux of T4 and T3 in thyroid hormone target cells tide (OATP)1C1 and, recently, SLC17A4 (10–13). (Fig. 1) (3–5). Plasma membrane transporters need Another group of discoveries involved the iden- to be distinguished from serum thyroid hormone– tification of diseases associated with mutations in binding proteins (such as thyroid hormone– thyroid hormone transporters. Mutations in MCT8 binding globulin), which were previously called are associated with severe intellectual disability serum thyroid hormone transporters (6). The accompanied by a specific thyroid hormone fin- transport of thyroid hormones in serum is exten- gerprint in the blood (14, 15). These publications sively reviewed elsewhere (6) and falls beyond the started a new era because they provided ultimate scope of this review. There is increased awareness proof for the physiological relevance of thyroid of nongenomic effects of thyroid hormones whose hormone transporters. Recently, the first case of actions involve receptors in the plasma membrane, OATP1C1 deficiency has been reported presenting mitochondria, or cytoplasm (7). with progressive neurodegeneration and cerebral It had been thought for many decades that hypometabolism (16). thyroid hormones could enter their target cells In addition, different models have been es- through passive diffusion given the lipophilic na- tablished to study the role of thyroid hormone ture of iodothyronines. However, accumulating ev- transporters in health and disease. Particularly, idence published from the 1970s onward provided various experimental models have enlarged the evidence that thyroid hormone transfer across the understanding on the (tissue-specific) contri- plasma membrane requires a carrier-mediated bution of various thyroid hormone transporters mechanism, and that the role of passive diffusion, in the regulation of tissue thyroid hormone if any, is limited (8, 9). These studies indicated that state. Novel global and tissue-specific trans- the transport of thyroid hormone into cells is a porter knock-out (ko) mouse models have been saturable process, may be inhibited by aromatic generated and characterized over recent years and/or aliphatic amino acids, and may depend on (17–27). In addition, zebrafish and chicken are Na+ in some cell types. Yet, the identity of thyroid emerging as complementary vertebrate models to hormone plasma membrane transporter proteins study the role of thyroid hormone transporters. started being elucidated in the late 1990s. These Finally, redifferentiated patient-derived induced 2 Groeneweg et al. Thyroid Hormone Transporters Endocrine Reviews, April 2020, 41(2):1–56 Review Downloaded from https://academic.oup.com/edrv/article-abstract/41/2/bnz008/5637505 by Erasmus University Rotterdam user on 04 March 2020 Figure 1. Transport, metabolism, and action of thyroid hormone in a thyroid hormone target cell. Transport across the plasma mem- brane is facilitated by transporter proteins. Deiodination of thyroid hormones is catalyzed by iodothyronine deiodinases (type 1, D1; type 2, D2; type 3, D3). T3 enters the nucleus, where it binds its receptor (TR) that forms a heterodimer with RXR at T3-responsive elements (TREs) in the promotor regions of T3 target genes. mRNA indicates messenger RNA. pluripotent stem cells (iPSCs) have been em- L-type amino acid transporters (LATs), and ployed as a human model to understand disease monocarboxylate transporters (SLC16 also known (28–32). as MCTs). Drug therapy development programs followed Most thyroid hormone transporters have been the identification of MCT8 deficiency. The identified through in vitro overexpression studies 125 abovementioned models largely facilitated testing in cell lines or Xenopus oocytes, using [ I]–radio- potential therapeutic intervention for transporter labeled iodothyronines to measure cellular thyroid defects. Such preclinical studies indicated that hormone uptake. Such cellular expression systems are the use of thyroid hormone analogues may hold indispensable to ensure proper protein conformation strong therapeutic potential in MCT8 deficiency, and function. The substrate specificity of transporters leading to a phase 2 clinical trial on the application is generally determined in direct uptake studies with of triiodothyroacetic acid (Triac) (33). In addition, the compounds of interest or indirectly in (cis-)inhibi- chemical chaperones and gene therapy are under tion studies. Cellular thyroid hormone homeostasis in active investigation (34–37). these systems depends not only on the overexpressed Here we provide
Load more

Recommended publications
  • The Concise Guide to Pharmacology 2019/20
    Edinburgh Research Explorer THE CONCISE GUIDE TO PHARMACOLOGY 2019/20 Citation for published version: Cgtp Collaborators 2019, 'THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters', British Journal of Pharmacology, vol. 176 Suppl 1, pp. S397-S493. https://doi.org/10.1111/bph.14753 Digital Object Identifier (DOI): 10.1111/bph.14753 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L
    [Show full text]
  • Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon
    Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon To cite this version: Quentin Verdon. Towards the Elucidation of Orphan Lysosomal Transporters. Cancer. Université Paris Saclay (COmUE), 2016. English. NNT : 2016SACLS144. tel-01827233 HAL Id: tel-01827233 https://tel.archives-ouvertes.fr/tel-01827233 Submitted on 2 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. NNT : 2016SACLS144 THESE DE DOCTORAT DE L’UNIVERSITE PARIS-SACLAY PREPAREE A L’UNIVERSITE PARIS-SUD ECOLE DOCTORALE N°568 BIOSIGNE | Signalisations et réseaux intégratifs en biologie Spécialité de doctorat : aspects moléculaires et cellulaires de la biologie Par Mr Quentin Verdon Towards the elucidation of orphan lysosomal transporters: several shots on target and one goal Thèse présentée et soutenue à Paris le 29/06/2016 » : Composition du Jury : Mr Le Maire Marc Professeur, Université Paris-Sud Président Mr Birman Serge Directeur de recherche, CNRS Rapporteur Mr Murray James Assistant professor, Trinity college Dublin Rapporteur Mr Goud Bruno Directeur de recherche, CNRS Examinateur Mr Gasnier Bruno Directeur de recherche, CNRS Directeur de thèse Mme Sagné Corinne Chargée de recherche, INSERM Co-directeur de thèse Table of contents Remerciements (acknowledgements) 6 Abbreviations 7 Abstracts 10 Introduction 12 1 Physiology of lysosomes 12 1.1 Discovery and generalities 12 1.2 Degradative function 13 1.3.
    [Show full text]
  • Toxicological Profile for Nitrate and Nitrite
    NITRATE AND NITRITE 29 3. HEALTH EFFECTS 3.1 INTRODUCTION The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of nitrate and nitrite. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, reproductive, developmental, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear.
    [Show full text]
  • Sialic Acid Storage Disease
    Sialic acid storage disease Description Sialic acid storage disease is an inherited disorder that primarily affects the nervous system. People with sialic acid storage disease have signs and symptoms that may vary widely in severity. This disorder is generally classified into one of three forms: infantile free sialic acid storage disease, Salla disease, and intermediate severe Salla disease. Infantile free sialic acid storage disease (ISSD) is the most severe form of this disorder. Babies with this condition have severe developmental delay, weak muscle tone ( hypotonia), and failure to gain weight and grow at the expected rate (failure to thrive). They may have unusual facial features that are often described as "coarse," seizures, bone malformations, an enlarged liver and spleen (hepatosplenomegaly), and an enlarged heart (cardiomegaly). The abdomen may be swollen due to the enlarged organs and an abnormal buildup of fluid in the abdominal cavity (ascites). Affected infants may have a condition called hydrops fetalis in which excess fluid accumulates in the body before birth. Children with this severe form of the condition usually live only into early childhood. Salla disease is a less severe form of sialic acid storage disease. Babies with Salla disease usually begin exhibiting hypotonia during the first year of life and go on to experience progressive neurological problems. Signs and symptoms of Salla disease include intellectual disability and developmental delay, seizures, problems with movement and balance (ataxia), abnormal tensing of the muscles (spasticity), and involuntary slow, sinuous movements of the limbs (athetosis). Individuals with Salla disease usually survive into adulthood. People with intermediate severe Salla disease have signs and symptoms that fall between those of ISSD and Salla disease in severity.
    [Show full text]
  • Sialin (SLC17A5) Functions As a Nitrate Transporter in the Plasma Membrane
    Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane Lizheng Qina,1, Xibao Liub,1, Qifei Suna, Zhipeng Fana, Dengsheng Xiaa, Gang Dinga, Hwei Ling Ongb, David Adamsc, William A. Gahlc, Changyu Zhengb, Senrong Qia, Luyuan Jina, Chunmei Zhanga, Liankun Gud, Junqi Hee, Dajun Dengd,2, Indu S. Ambudkarb,2, and Songlin Wanga,e,2 aSalivary Gland Disease Center and Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Capital Medical University School of Stomatology, Beijing 100050, China; bMolecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892; cMedical Genetics Branch, National Human Genome Research Institute, Bethesda, MD 20892; dKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing 100142, China; and eDepartment of Biochemistry and Molecular Biology, Capital Medical University School of Basic Medicine, Beijing 100069, China Edited by Mark Gladwin, University of Pittsburg Medical Center, Pittsburgh, PA and accepted by the Editorial Board June 5, 2012 (received for review October 13, 2011) In vivo recycling of nitrate (NO −) and nitrite (NO −) is an important Nitrate uptake into salivary glands represents the key initial step 3 2 − alternative pathway for the generation of nitric oxide (NO) and in NO clearance from the serum; however, the mechanism me- 3 − maintenance of systemic nitrate–nitrite–NO balance. More than diating transport of NO3 in salivary gland epithelial cells has not − − fl 25% of the circulating NO3 is actively removed and secreted by yet been established. In this study, we examined NO3 in ux in − + salivary glands. Oral commensal bacteria convert salivary NO3 to salivary gland cells.
    [Show full text]
  • Potential Roles of Nitrate and Nitrite in Nitric Oxide Metabolism in the Eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M
    www.nature.com/scientificreports OPEN Potential roles of nitrate and nitrite in nitric oxide metabolism in the eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M. Parver3 & Alan N. Schechter1* Nitric oxide (NO) signaling has been studied in the eye, including in the pathophysiology of some eye diseases. While NO production by nitric oxide synthase (NOS) enzymes in the eye has been − characterized, the more recently described pathways of NO generation by nitrate ( NO3 ) and nitrite − (NO2 ) ions reduction has received much less attention. To elucidate the potential roles of these pathways, we analyzed nitrate and nitrite levels in components of the eye and lacrimal glands, primarily in porcine samples. Nitrate and nitrite levels were higher in cornea than in other eye parts, while lens contained the least amounts. Lacrimal glands exhibited much higher levels of both ions compared to other organs, such as liver and skeletal muscle, and even to salivary glands which are known to concentrate these ions. Western blotting showed expression of sialin, a known nitrate transporter, in the lacrimal glands and other eye components, and also xanthine oxidoreductase, a nitrate and nitrite reductase, in cornea and sclera. Cornea and sclera homogenates possessed a measurable amount of nitrate reduction activity. These results suggest that nitrate ions are concentrated in the lacrimal glands by sialin and can be secreted into eye components via tears and then reduced to nitrite and NO, thereby being an important source of NO in the eye. Te NO generation pathway from L-arginine by endogenous NOS enzymes under normoxic conditions has been central in identifying the physiological roles of NO in numerous biological processes1.
    [Show full text]
  • Characterization of Centrally Expressed Solute Carriers
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1215 Characterization of Centrally Expressed Solute Carriers Histological and Functional Studies with Transgenic Mice SAHAR ROSHANBIN ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-9555-8 UPPSALA urn:nbn:se:uu:diva-282956 2016 Dissertation presented at Uppsala University to be publicly examined in B:21, Husargatan. 75124 Uppsala, Uppsala, Friday, 3 June 2016 at 13:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Biträdande professor David Engblom (Institutionen för klinisk och experimentell medicin, Cellbiologi, Linköpings Universitet). Abstract Roshanbin, S. 2016. Characterization of Centrally Expressed Solute Carriers. Histological and Functional Studies with Transgenic Mice. (. His). Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1215. 62 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9555-8. The Solute Carrier (SLC) superfamily is the largest group of membrane-bound transporters, currently with 456 transporters in 52 families. Much remains unknown about the tissue distribution and function of many of these transporters. The aim of this thesis was to characterize select SLCs with emphasis on tissue distribution, cellular localization, and function. In paper I, we studied the leucine transporter B0AT2 (Slc6a15). Localization of B0AT2 and Slc6a15 in mouse brain was determined using in situ hybridization (ISH) and immunohistochemistry (IHC), localizing it to neurons, epithelial cells, and astrocytes. Furthermore, we observed a lower reduction of food intake in Slc6a15 knockout mice (KO) upon intraperitoneal injections with leucine, suggesting B0AT2 is involved in mediating the anorexigenic effects of leucine.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Frontiersin.Org 1 April 2015 | Volume 9 | Article 123 Saunders Et Al
    ORIGINAL RESEARCH published: 28 April 2015 doi: 10.3389/fnins.2015.00123 Influx mechanisms in the embryonic and adult rat choroid plexus: a transcriptome study Norman R. Saunders 1*, Katarzyna M. Dziegielewska 1, Kjeld Møllgård 2, Mark D. Habgood 1, Matthew J. Wakefield 3, Helen Lindsay 4, Nathalie Stratzielle 5, Jean-Francois Ghersi-Egea 5 and Shane A. Liddelow 1, 6 1 Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC, Australia, 2 Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark, 3 Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, 4 Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland, 5 Lyon Neuroscience Research Center, INSERM U1028, Centre National de la Recherche Scientifique UMR5292, Université Lyon 1, Lyon, France, 6 Department of Neurobiology, Stanford University, Stanford, CA, USA The transcriptome of embryonic and adult rat lateral ventricular choroid plexus, using a combination of RNA-Sequencing and microarray data, was analyzed by functional groups of influx transporters, particularly solute carrier (SLC) transporters. RNA-Seq Edited by: Joana A. Palha, was performed at embryonic day (E) 15 and adult with additional data obtained at University of Minho, Portugal intermediate ages from microarray analysis. The largest represented functional group Reviewed by: in the embryo was amino acid transporters (twelve) with expression levels 2–98 times Fernanda Marques, University of Minho, Portugal greater than in the adult. In contrast, in the adult only six amino acid transporters Hanspeter Herzel, were up-regulated compared to the embryo and at more modest enrichment levels Humboldt University, Germany (<5-fold enrichment above E15).
    [Show full text]
  • The Lysosomal Sialic Acid Transporter Sialin Is Required for Normal CNS Myelination
    The Journal of Neuroscience, December 9, 2009 • 29(49):15355–15365 • 15355 Neurobiology of Disease The Lysosomal Sialic Acid Transporter Sialin Is Required for Normal CNS Myelination Laura M. Prolo,1 Hannes Vogel,2 and Richard J. Reimer1 1Department of Neurology and Neurological Sciences and Graduate Program in Neuroscience and 2Departments of Pathology and Pediatrics, Stanford University School of Medicine, Stanford, California 94305 Salla disease and infantile sialic acid storage disease are autosomal recessive lysosomal storage disorders caused by mutations in the gene encoding sialin, a membrane protein that transports free sialic acid out of the lysosome after it is cleaved from sialoglycoconjugates undergoing degradation. Accumulation of sialic acid in lysosomes defines these disorders, and the clinical phenotype is characterized by neurodevelopmental defects, including severe CNS hypomyelination. In this study, we used a sialin-deficient mouse to address how loss of sialin leads to the defect in myelination. Behavioral analysis of the sialin ؊/؊ mouse demonstrates poor coordination, seizures, and premature death. Analysis by histology, electron microscopy, and Western blotting reveals a decrease in myelination of the CNS but normal neuronal cytoarchitecture and normal myelination of the PNS. To investigate potential mechanisms underlying CNS hypomyeli- nation, we studied myelination and oligodendrocyte development in optic nerves. We found reduced numbers of myelinated axons in optic nerves from sialin ؊/؊ mice, but the myelin that was present appeared grossly normal. Migration and density of oligodendrocyte precursorcellswerenormal;however,amarkeddecreaseinthenumberofpostmitoticoligodendrocytesandanassociatedincreaseinthe number of apoptotic cells during the later stages of myelinogenesis were observed. These findings suggest that a defect in maturation of cells in the oligodendrocyte lineage leads to increased apoptosis and underlies the myelination defect associated with sialin loss.
    [Show full text]
  • Novel Exc Genes Involved in Formation of the Tubular Excretory 2 Canals of C
    bioRxiv preprint doi: https://doi.org/10.1101/359653; this version posted June 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Novel exc Genes Involved in Formation of the Tubular Excretory 2 Canals of C. elegans 3 4 Hikmat Al-Hashimi*, Travis Chiarelli*,1, Erik A. Lundquist*, and Matthew Buechner* 5 *Dept. of Molecular Biosciences, University of Kansas, Lawrence, KS, 66045, USA 6 7 1Present address: Dept. of Biological Sciences, University of Idaho, Moscow, ID, 83843, USA 8 9 Page 1 bioRxiv preprint doi: https://doi.org/10.1101/359653; this version posted June 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 10 Short Title: 11 RNAi Screen for Tubulogenesis Genes 12 13 Keywords 14 Tubulogenesis; lumen formation; endosomes; EXC-5; Charcot-Marie-Tooth Syndrome 15 Type 4H 16 17 Corresponding Author: 18 Matthew Buechner 19 Dept. of Molecular Biosciences 20 1200 Sunnyside Avenue, 8035 Haworth Hall 21 University of Kansas 22 Lawrence, KS, 66045-7534 23 [email protected] 24 (785) 864-4328 25 Page 2 bioRxiv preprint doi: https://doi.org/10.1101/359653; this version posted June 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Carla Freire Celedonio Fernandes Molecular Characterization And
    www.doktorverlag.de [email protected] Tel: 0641-5599888 Fax: -5599890 Tel: D-35396 GIESSEN ST AU FEN BER G R I N G 1 5 VVB LAUFERSWEILERVERLAG VVB LAUFERSWEILER VERLAG VVB LAUFERSWEILER édition scientifique 9783835 952300 ISBN 3-8359-5230-7 ISBN VVB CARLA FREIRE CELEDONIO FERNANDE S SLC10A4 AND SLC10A5 Carla FreireCeledonioFernandes Expression ofTwoNewMembers of theSLC10TransporterFamily: Molecular Characterizationand VVB LAUFERSWEILER VERLAG VVB LAUFERSWEILER SLC10A4 andSLC10A5 Doktorgrades der Naturwissenchaften dem Fachbereich Pharmazie der Dissertation zur Erlangung des édition scientifique édition Philipps-Universität Marburg (Dr. rer. Nat.) Das Werk ist in allen seinen Teilen urheberrechtlich geschützt. Jede Verwertung ist ohne schriftliche Zustimmung des Autors oder des Verlages unzulässig. Das gilt insbesondere für Vervielfältigungen, Übersetzungen, Mikroverfilmungen und die Einspeicherung in und Verarbeitung durch elektronische Systeme. 1. Auflage 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the Author or the Publishers. 1st Edition 2007 © 2007 by VVB LAUFERSWEILER VERLAG, Giessen Printed in Germany VVB LAUFERSWEILER VERLAG édition scientifique STAUFENBERGRING 15, D-35396 GIESSEN Tel: 0641-5599888 Fax: 0641-5599890 email: [email protected] www.doktorverlag.de Aus dem Institut für Pharmakologie und Toxikologie der Philipps-Universität Marburg Betreuer: Prof. Dr. Dr. Joseph Krieglstein und dem Institut für Pharmakologie und Toxikologie der Justus-Liebig-Universität Gießen Betreuer: Prof. Dr. Ernst Petzinger Molecular Characterization and Expression of Two New Members of the SLC10 Transporter Family: SLC10A4 and SLC10A5 Dissertation zur Erlangung des Doktorgrades der Naturwissenchaften (Dr.
    [Show full text]